奥特曼打造脑机接口初创挑战Neuralink，马斯克公开否定其技术思路

Core Insights - The article discusses the competition between Sam Altman, CEO of OpenAI, and Elon Musk in the brain-computer interface (BCI) sector, highlighting the recent developments at Merge Labs, a company co-founded by Altman [1][2][5]. Company Developments - Merge Labs has recruited Mikhail Shapiro, a prominent researcher from Caltech, known for his work in non-invasive brain imaging and gene therapy [1][5][7]. - Altman is expected to serve as the chairman of Merge Labs, while Shapiro is anticipated to play a key leadership role in the company [5]. - Merge Labs is reportedly in discussions for a $250 million funding round led by OpenAI, which would value the company at $850 million [5]. Technology Approach - Merge Labs aims to develop a non-invasive brain-computer interface using "gene therapy + ultrasound" methods, contrasting with Neuralink's invasive techniques [5][11]. - Shapiro's research focuses on using ultrasound to interact with the brain without the need for surgical procedures, which is a significant departure from Neuralink's approach [7][12]. Industry Context - The article outlines the ongoing debate between invasive and non-invasive BCI technologies, with the former posing higher risks and potential complications [12]. - Altman has publicly expressed his preference for non-invasive methods, indicating a strategic direction for Merge Labs that may influence the future of human-AI integration [5][12].